Coherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
List view / Grid view
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
22 December 2023 | By
Download this eBook for FREE. Explore cutting-edge immuno-oncology insights through exclusive interviews and studies by leading experts in the field.
Tune into this podcast to hear experts discussing the tumour microenvironment in immuno-oncology!
Researchers from UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine have made a discovery linking the notorious cancer-causing gene, Myc, to the process of ageing.
Important step achieved by US researchers as stable and potent immune therapy delivery system eradicates tumours in mouse models of melanoma, colon, and breast cancer, while preventing the formation of future tumour.
Australian researchers analyse the way specialised white blood cells produce an immune response, which could lead to the development of preventative treatments for cancer and infectious diseases.